Arena Pharmaceuticals
 | |
| Public (NASDAQ: ARNA) | |
| Industry | Biotechnology |
| Headquarters | San Diego, California, U.S. |
Key people |
|
| Products | in development |
| Revenue |
 US$27.6M (FY 2012)[1] |
 US$-57M (FY 2012)[1] | |
|
US$-85.5M (FY 2012)[1] | |
| Total assets |
US$261M (FY 2012)[2] |
| Total equity |
US$98.6M (FY 2012)[2] |
| Website |
www |
Arena Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, California. The company is developing oral medications that target G-protein-coupled receptors. On June 27, 2012, the FDA approved lorcaserin, initially sold under the brand name Belviq with a launch sales force commitment of 200.[3][4] Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
As of September 2014, Arena has other drugs in their pipeline that have not yet been approved by the U.S. Food and Drug Administration, namely:[5]
- Temanogrel, Phase I, Thrombotic Diseases.
- Ralinepag, Planned Phase II trial, Pulmonary Arterial Hypertension.
- APD334, Phase I, Autoimmune Diseases
- APD371, Phase I, Pain
See also
References
- ↑ 1.0 1.1 1.2 Arena Pharmaceuticals (ARNA) annual SEC income statement filing via Wikinvest.
- ↑ 2.0 2.1 Arena Pharmaceuticals (ARNA) annual SEC balance sheet filing via Wikinvest.
- ↑ "FDA approves Belviq to treat some overweight or obese adults" (Press release). US FDA. June 27, 2012. Retrieved January 3, 2014.
- ↑ Osborne, Spencer (12 December 2014). "Contrave Sales Continue To Impress". Seeking Alpha.
- ↑ http://www.arenapharm.com/programs